No Data
No Data
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Express News | JPMorgan Chase & Co's Long Position in H-Shares of Asymchem Laboratories Tianjin Decreases to 8.90% on Aug 1 From 9.83% - HKEX
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Market Cap Surged CN¥2.3b Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Asymchem Inaugurates Its First European Small Molecule Development and API Pilot Plant Manufacturing Site at Discovery Park in Sandwich, Kent, UK
Asymchem Laboratories (002821.SZ): Cumulative expenditure of 999.6 million yuan to repurchase 12,300,700 shares.
Asymchem Laboratories (002821.SZ) announced that as of July 31, 2024, the company accumulated 12.3007 million shares of the company's A shares through the repurchase of special securities accounts under the centralized bidding method, accounting for 3.5976% of the company's total A shares. The highest fill price was 102.00 yuan/share, the lowest fill price was 71.65 yuan/share, and the total amount paid was 0.9996 billion yuan (excluding transaction costs).
No Data